We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Synthetic Fatty Acid Derivatives Display Anti-Cancer Potential

By LabMedica International staff writers
Posted on 26 Jul 2018
Print article
Image: A ball-and-stick model of the docosahexaenoic acid (DHA) molecule. DHA is an omega-3 fatty acid that is a primary structural component of the human brain, cerebral cortex, skin, and retina (Photo courtesy of Wikimedia Commons).
Image: A ball-and-stick model of the docosahexaenoic acid (DHA) molecule. DHA is an omega-3 fatty acid that is a primary structural component of the human brain, cerebral cortex, skin, and retina (Photo courtesy of Wikimedia Commons).
Metabolites produced during digestion of omega-3 fatty acids have been found to have anti-cancer properties, and their synthetic derivatives have the potential to be developed into potent chemotherapeutic drugs.

Dietary omega-3 fatty acids, such as docosahexaenoic acid (DHA), have been shown to suppress tumor growth through their conversion to epoxide metabolites. Alternatively, DHA is converted enzymatically into docosahexaenoylethanolamide (DHEA), an endocannabinoid with anti-proliferative activity.

Investigators at the University of Illinois (Champaign-Urbana, USA) had previously described a novel class of anti-inflammatory DHEA-epoxide derivative called epoxydocospentaenoic-ethanolamide (EDP-EA) that contained both ethanolamide and epoxide moieties. To expand those findings they examined the anti-tumorigenic properties of EDP-EAs in an osteosarcoma (OS) mouse model.

The investigators showed an approximately 80% increase in EDP-EAs in metastatic versus normal lungs of mice. In addition they found significant differences in the apoptotic and anti-migratory potencies of different EDP-EA structural isomers, which were partially mediated through the cannabinoid receptor 1 (CB1). The cannabinoid receptor is represented in relatively high density on the surface of cancer cells.

The investigators then synthesized derivatives of the most pro-apoptotic isomer. These derivatives were found to display reduced hydrolytic susceptibility to fatty acid amide hydrolase (FAAH) and increased CB1-selective binding.

"We have a built-in endocannabinoid system which is anti-inflammatory and pain-reducing. Now we see it is also anti-cancer, stopping the cells from proliferating or migrating," said senior author Dr. Aditi Das, professor of comparative biosciences at the University of Illinois. "These molecules could address multiple problems: cancer, inflammation, and pain."

"The dramatic increase indicated that these molecules were doing something to the cancer - but we did not know if it was harmful or good," said Dr. Das. "We asked, are they trying to stop the cancer, or facilitating it? So we studied the individual properties and saw that they are working against the cancer in several ways. Dietary consumption of omega-3 fatty acids can lead to the formation of these substances in the body and may have some beneficial effects. However, if you have cancer, you want something concentrated and fast acting. That is where the endocannabinoid epoxide derivatives come into play - you could make a concentrated dose of the exact compound that is most effective against the cancer. You could also mix this with other drugs such as chemotherapies."

Related Links:
University of Illinois

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: The fastGEN BCR::ABL1 Cancer kit offers a way to personalize treatment strategies for leukemia (Photo courtesy of BioVendor MDx)

First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment

The BCR::ABL1 fusion gene plays a key role in the pathogenesis of several blood cancers, particularly chronic myeloid leukemia (CML). This gene results from a chromosomal translocation that causes constitutive... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The new method is quick and easy, and can also be used by non-medical personnel. (Photo courtesy of Zoratto et al. Advanced Science 2024, edited)

New Blood Test Device Modeled on Leeches to Help Diagnose Malaria

Many individuals have a fear of needles, making the experience of having blood drawn from their arm particularly distressing. An alternative method involves taking blood from the fingertip or earlobe,... Read more